Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.
1. An antibody that specifically binds to a leucine-rich repeat containing G-protein-coupled receptor 4 (LGR4) polypeptide having an EC50 for LGR4binding less than 2 nM and greater than or equal to about 64 pM, and activity to inhibit growth of a neoplastic cell in vivo, wherein the antibody comprises:
a first light chain complementarity determining region (CDR) polypeptide comprising SEQ ID NO:14;
a second light chain CDR polypeptide comprising SEQ ID NO:15;
a third light chain CDR polypeptide comprising SEQ ID NO: 16;
a first heavy chain CDR polypeptide comprising SEQ ID NO:17;
a second heavy chain CDR polypeptide comprising SEQ ID NO:18; and
a third heavy chain CDR polypeptide comprising SEQ ID NO:19.
2. The antibody of claim 1 comprising a humanized polypeptide selected from the group consisting of a VL polypeptide comprising SEQ ID NO:11, a VH polypeptide comprising SEQ ID NO:12, and a VH polypeptide comprising SEQ ID NO:13.
3. The antibody of claim 1 comprising:
(a) a VL polypeptide comprising SEQ ID NO:11, and
(b) a VH polypeptide selected from the group consisting of SEQ ID NO.s:12 and 13.
4. The antibody of claim 1 comprising a polypeptide selected from the group consisting of a heavy chain comprising SEQ ID NO:09, and a light chain comprising SEQ ID NO:10.
5. The antibody of claim 1 comprising:
(a) a heavy chain polypeptide comprising SEQ ID NO:09, and
(b) a light chain polypeptide comprising SEQ ID NO:10.
6. The antibody of claim 1 having an EC50 for LGR4 binding of less than 1 nM.
7. The antibody of claim 1 having a K D for LGR4 binding of about 1.5 nM.
8. The antibody of claim 1 lacking activity to inhibit binding between LGR4 and a R-spondin protein.
9. The antibody of claim 1 lacking activity to inhibit binding between LGR4 and a R-spondin-4 protein.
10. The antibody of claim 1 , wherein the neoplastic cell is selected from the group consisting of lung tumor cell, breast tumor cell, ovarian tumor cell, colon tumor cell, and pancreatic tumor cell.
11. The antibody of claim 1 , wherein the neoplastic cell is selected from the group consisting of a triple negative breast cancer cell, a small cell lung cancer cell, a cancer stem cell, a cancer stem cell comprises CD44+ and CD44+/CD24−, and a colon cancer cell having a mutation in a gene selected from the group consisting of K-Ras, P13K, PTEN, p53 and APC.
12. The antibody of claim 1 comprising activity to inhibit growth of a tumor comprising the neoplastic cell.
13. The antibody of claim 1 comprising activity to reduce the frequency of cancer stem cells in a tumor.
14. The antibody of claim 1 comprising activity to inhibit growth of a tumor comprising the neoplastic cell by about 25% compared to the growth of a tumor not contacted with the antigen binding protein or fragment thereof.
15. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.
16. The antibody of claim 15 , wherein the monoclonal antibody is selected from the group consisting of 1C5 and 8F3.
17. The antibody of claim 1 , wherein the antibody is a humanized monoclonal antibody.
18. The antibody of claim 17 , wherein the humanized monoclonal antibody is selected from the group consisting of 1C5HE and 1C5HG.
19. A monoclonal antibody that specifically binds to a leucine-rich repeat containing G-protein-coupled receptor 4 (LGR4) protein, said antibody comprising:
a first light chain complementarity determining region (CDR) polypeptide comprising SEQ ID NO:14;
a second light chain CDR polypeptide comprising SEQ ID NO:15;
a third light chain CDR polypeptide comprising SEQ ID NO: 16;
a first heavy chain CDR polypeptide comprising SEQ ID NO:17;
a second heavy chain CDR polypeptide comprising SEQ ID NO:18; and
a third heavy chain CDR polypeptide comprising SEQ ID NO:19.
20. The monoclonal antibody of claim 19 , having an EC50 for LGR4 binding less than 2 nM.
21. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
22. A method of inhibiting growth of a neoplastic cell comprising contacting the cell with the antibody of claim 1 .
23. The method of claim 22 , wherein the neoplastic cell is selected from the group consisting of lung tumor cell, breast tumor cell, ovarian tumor cell, colon tumor cell, and pancreatic tumor cell.
24. The method of claim 22 , wherein the neoplastic cell is selected from the group consisting of a triple negative breast cancer cell, a small cell lung cancer cell, a cancer stem cell, a cancer stem cell comprising CD44+ and CD44+/CD24−, and a colon cancer cell having a mutation in a gene selected from the group consisting of K-Ras, P13K, PTEN, p53 and APC.
25. A method of treating a tumor in a subject comprising administering to the subject in need thereof an effective amount of the antibody of claim 1 .
26. The method of claim 25 , wherein the tumor is selected from the group consisting of lung tumor, breast tumor, ovarian tumor, colon tumor, and pancreatic tumor.
27. The method of claim 25 , wherein the tumor is selected from the group consisting of a triple negative breast cancer tumor, a small cell lung cancer tumor, a population of cancer stem cells, a population of cancer stem cells comprising CD44+ and CD44+/CD24−, and a colon cancer tumor having a mutation in a gene selected from the group consisting of K-Ras, P13K, PTEN, p53 and APC.
28. The method of claim 25 , wherein the antibody inhibits growth of the tumor.
29. The method of claim 25 , wherein the antibody reduces the number of cancer stem cells in a tumor.
30. The method of claim 25 , wherein the antibody inhibits growth of the tumor by about 25% compared to the growth of a tumor not contacted with the antigen binding protein or fragment thereof.